Peptides Academy
CJC-1295 No DAC (Mod GRF 1-29)
Research-Grade
CJC-1295 without DAC, commonly sold as Modified GRF (1-29) or Mod GRF 1-29, is a synthetic analog of the first 29 amino acids of human growth-hormone-releasing hormone (GHRH) carrying four amino-acid substitutions. It corresponds to the peptide portion of CJC-1295, which its developers described as a tetrasubstituted form of human GRF(1-29) to which an albumin-binding maleimido group was added; the albumin-conjugated versions showed enhanced stability against the enzyme dipeptidylpeptidase-IV. Unlike CJC-1295 with DAC — which has randomized healthy-volunteer data showing GH and IGF-1 increases lasting days after a single injection — the no-DAC peptide has essentially no peer-reviewed human pharmacokinetic or clinical trial data indexed in PubMed. Its half-life, optimal dosing and safety in people have not been established. It has been identified, alongside GHRP-2, GHRP-6 and ipamorelin analogs, in seized doping material. It is commonly paired with a ghrelin-receptor agonist such as ipamorelin. The rationale comes from older physiology: in healthy men, GHRH and the GH-releasing peptide GHRP-6 stimulated GH synergistically, suggesting independent pathways. The specific CJC-1295 no-DAC plus ipamorelin combination has not been tested in published human trials. The FDA lists CJC-1295 among bulk drug substances reviewed for compounding safety risks; it is not an approved medicine.
Specifications
| Origin / Manufacturer | Synthetic |
| Active Components | CJC-1295 no-DAC (Modified GRF 1-29) |
| Storage | Lyophilized: room temperature. Reconstituted: 2–8°C |
| Shelf Life | Lyophilized 24+ months; reconstituted 21–30 days refrigerated |
| Form Factor | Lyophilized powder (2 mg or 5 mg vial) |
Frequently Asked Questions
Sources & References
Every clinical claim on this page traces to a primary peer-reviewed source.
- 1Jetté L, Léger R, Thibaudeau K, et al.. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. doi:10.1210/en.2004-1286 PMID:15817669
- 2Teichman SL, Neale A, Lawrence B, et al.. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536 PMID:16352683
- 3Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-7. doi:10.1210/jc.2006-1702 PMID:17018654
- 4Bowers CY, Reynolds GA, Durham D, et al.. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. The Journal of Clinical Endocrinology and Metabolism. 1990;70(4):975-82. doi:10.1210/jcem-70-4-975 PMID:2108187
- 5Gajda PM, Holm NB, Hoej LJ, et al.. Glycine-modified growth hormone secretagogues identified in seized doping material. Drug Testing and Analysis. 2019;11(2):350-354. doi:10.1002/dta.2489 PMID:30136411
- 6U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA Human Drug Compounding. 2026.
Reviewed by
Clinical Research Review Board
Pharmacology & Endocrinology Review
All clinical claims cross-checked against primary sources. Read our editorial policy →
Related Peptides
CJC-1295 + Ipamorelin
Research-Grade
The most widely used GHRH + GHRP stack — CJC-1295 extends GHRH half-life while Ipamorelin selectively amplifies GH pulses without disturbing cortisol or prolactin.
GHRP-2
Research-Grade
A synthetic growth-hormone-releasing hexapeptide and ghrelin-receptor agonist that produces strong GH release in humans but also raises prolactin, ACTH and cortisol; research-only in the US.
GHRP-6
Research-Grade
The original synthetic growth-hormone-releasing hexapeptide (His-DTrp-Ala-Trp-DPhe-Lys-NH2): a potent GH secretagogue in humans that also raises prolactin and cortisol and stimulates eating in animal studies; research-only in the US.
Ipamorelin
Research-Grade
The most selective GHRP (growth-hormone-releasing peptide) — amplifies GH pulses via ghrelin/GHSR receptor without meaningful cortisol, prolactin, or aldosterone crosstalk.
Sermorelin
Research-Grade
The first synthetic GHRH analog approved for clinical use — GHRH (1-29) NH₂, the minimum active sequence. Shorter-acting than tesamorelin or CJC-1295.
Tesamorelin
Egrifta
FDA-approved synthetic GHRH analog (Egrifta) indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy; also studied in HIV-associated fatty liver disease and cognition in older adults.